BSE filing, NSE: KPL. Summary written from the filing by ALFA Finder's alert engine.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,689.65
- Market cap
- ₹3,828 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 47.2×Sector 42.0×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Business Update
Kwality Pharmaceuticals secured EU-GMP approval from Hungary for its Cephalosporin and Oncology facilities. This expands its EU-approved manufacturing footprint and positions it for global licensing opportunities.
Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Capacity Expansion
Kwality Pharmaceuticals acquired 4 acres adjacent to its Amritsar plant to build a fully automated facility with 10+ production lines. Completion is targeted by Q4 FY2028 with full operations by Q2 FY2029.
- Execution
- Completion by Q4 FY2028; full operations by Q2 FY2029
- manufacturing production lines (injectable + oral solid + ophthalmic)
- 10 production lines
Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.
Kwality Pharmaceuticals Earnings Call Transcript: Key Takeaways
Kwality Pharma Q1FY27 con-call highlights revision of FY27 revenue target to ₹700Cr+ with 26-27% EBITDA margins, driven by niche injectable registrations in LATAM and MENA regions.
- Call
- Guides 30% growth
Other board meeting date announcements
All →Focus Business Solution Board Meeting Date
Focus Business Solution Ltd intimated a board meeting on 12 November 2026 to consider unaudited financial statements for the half-year ended 30 September 2026. Investors should expect half-year results at that meeting.
Vasundhara Rasayans Board Meeting Date
Vasundhara Rasayans will hold a board meeting on 12 November 2026 to consider unaudited financial results for the quarter and half year ended 30 September 2026. The trading window is already closed until 48 hours after the results are declared.
Jindal Poly Investment & Finance Company Board Meeting Date
JINDAL POLY INVESTMENT AND FINANCE COMPANY LIMITED will hold a board meeting on 12 November 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. Trading window is closed from 1 October to 14 October 2026.
Jindal Photo Board Meeting Date
Jindal Photo will hold a board meeting on November 13, 2026 to consider Q2FY27 and H1 unaudited results. The trading window stays closed until 48 hours after the results declaration.
Manappuram Finance Board Meeting Date
Manappuram Finance will hold a board meeting on November 12, 2026 to consider Q2FY27 and H1 results and an interim dividend. The trading window stays closed until November 16, 2026.
Titagarh Rail Systems Board Meeting Date
Titagarh Rail Systems will consider half-yearly results for September 2026 at a board meeting on 10 November. Trading window closes from 1 October until 13 November 2026.